Printable Datasheet

Recombinant Transforming Growth Factor Beta 1 (TGFB1) (Marker of Tumor Invasiveness) Antibody [rTGFB17]

In Stock
Catalog Number Formulation Size Price
7040-MSM8-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$249.00
7040-MSM8-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$539.00
7040-MSM8-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$539.00
Flat Rate Domestic: $95 | Orders outside the US - Contact Us for Order Information | Ships next business day
Transforming Growth Factor Beta 1 Antibody in SDS-PAGE

Transforming Growth Factor Beta 1 Antibody in SDS-PAGE

SDS-PAGE Analysis of Purified Transforming Growth Factor Beta 1 Recombinant Mouse Monoclonal Antibody (rTGFB17). Confirmation of Purity and Integrity of Antibody.

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
IHC Protocol
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

Transforming growth factor beta (TGFB) is a potent cell regulatory polypeptide homodimer of 25 kD. It variably affects cell growth, differentiation and other aspects of cellular metabolism such as extracellular matrix production. Its effect depends upon the cell type and other growth factors present but in general, TGFB inhibits the growth of epithelial cells and stimulates the growth of mesenchymal cells.

Product Properties & Targets

Antibody Type
Mouse Monoclonals, Recombinant Mouse Monoclonals
Host
Mouse
Applications
Immunohistochemistry
Species Reactivity
Human
Research Areas
Cardiovascular, Developmental Biology, Immunology, AKT Signaling, Angiogenesis, Colon Cancer, Complement System, Cytokine Signaling, Infectious Disease, MAPK Signaling, Mesenchymal Stem Cell Differentiation, Neuroinflammation, Signal Transduction, Stem Cell Differentiation, Transcription Factors
Isotype / Light Chain
IgG2b / Kappa
Cellular Localization
Extracellular matrix, Extracellular space, Secreted
Gene Name
TGFB1
Positive Control
Human placenta.
Immunogen
Prokaryotic recombinant protein corresponding to the full length mature transforming growth factor beta1 molecule
Alternate Names
Transforming growth factor beta-1 proprotein | Latency-associated peptide | Transforming growth factor beta-1, Latency-associated peptide (LAP), Transforming growth factor beta-1 (TGF-beta-1), , TGFB | TGFB1 | Transforming growth factor beta-1 proprotein

Database Links

Entrez Gene ID
7040
SwissProt
P01137

Additional Information

Clone
rTGFB17
Chromosome Location
19q13.1
Mol. Weight of Antigen
13kDa
Expression System
CHO Cells

Related Antibodies

View All TGFB1 Antibodies

Functions

  • Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.
  • Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix (PubMed:28117447). Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1 (PubMed:2022183, PubMed:8617200, PubMed:8939931, PubMed:19750484, PubMed:22278742, PubMed:19651619). Interaction with LRRC33/NRROS regulates activation of TGF-beta-1 in macrophages and microglia (Probable). Interaction with LRRC32/GARP controls activation of TGF-beta-1 on the surface of activated regulatory T-cells (Tregs) (PubMed:19750484, PubMed:22278742, PubMed:19651619). Interaction with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-1 (PubMed:22278742, PubMed:28117447).
  • Multifunctional protein that regulates the growth and differentiation of various cell types and is involved in various processes, such as normal development, immune function, microglia function and responses to neurodegeneration (By similarity). Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains remain non-covalently linked rendering TGF-beta-1 inactive during storage in extracellular matrix (PubMed:29109152). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS that control activation of TGF-beta-1 and maintain it in a latent state during storage in extracellular milieus (PubMed:2022183, PubMed:8617200, PubMed:8939931, PubMed:19750484, PubMed:22278742, PubMed:19651619). TGF-beta-1 is released from LAP by integrins (ITGAV:ITGB6 or ITGAV:ITGB8): integrin-binding to LAP stabilizes an alternative conformation of the LAP bowtie tail and results in distortion of the LAP chain and subsequent release of the active TGF-beta-1 (PubMed:22278742, PubMed:28117447). Once activated following release of LAP, TGF-beta-1 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (PubMed:20207738). While expressed by many cells types, TGF-beta-1 only has a very localized range of action within cell environment thanks to fine regulation of its activation by Latency-associated peptide chain (LAP) and 'milieu molecules' (By similarity). Plays an important role in bone remodeling: acts as a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts (By similarity). Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner (By similarity). At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development (By similarity). At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells (By similarity). Stimulates sustained production of collagen through the activation of CREB3L1 by regulated intramembrane proteolysis (RIP) (PubMed:25310401). Mediates SMAD2/3 activation by inducing its phosphorylation and subsequent translocation to the nucleus (PubMed:25893292, PubMed:29483653, PubMed:30696809). Can induce epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types (PubMed:25893292, PubMed:30696809).

Key References

  • Miller, D.A., et al. 1990. Ann. N.Y. Acad. Sci. 593: 208-217.
  • Naef M, Ishiwata T, Friess H, et al . International Journal of Cancer. 71: 131–137 (1997 ).
  • McCune B K, Mullin B R, Flanders K C, et al . Human Pathology. 23 (1): 13–20 (1992).

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant Transforming Growth Factor Beta 1 (TGFB1) (Marker of Tumor Invasiveness) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK
Call Us Now: 1-866-2-NEOBIO (1-866-263-6246)
NeoBiotechnologies Logo
Company Info
Antibodies
Antibody Validation
Research Areas
Resources
Newsletter Signup Updates & Sales